黄栀花口服液联合阿莫西林克拉维酸钾治疗小儿急性上呼吸道感染的临床研究

Clinical study on Huangzhihua Oral Liquid combined with amoxicillin clavulanate potassium in treatment of acute upper respiratory tract infection in children

目的探讨黄栀花口服液联合阿莫西林克拉维酸钾干混悬剂医治小儿急性上呼吸道感染的临床效果。方法选取2017年1月—2018年1月在南阳市中心医院就诊的150例急性上呼吸道感染患儿,根据用药的差别分为治疗组、对照组(每组75名)。对照组患儿口服阿莫西林克拉维酸钾干混悬剂,7~12岁儿童1袋半/次,2~7岁1袋/次,9个月~2岁半袋/次,1次/12h;治疗组患儿在对照组基础上口服黄栀花口服液,2~3岁5m L/次,4~6岁10m L/次,7~10岁15m L/次,≥11岁20 mL/次,3次/d。两组患儿均经7 d治疗。观察并比较两组临床效果、症状消失时间及血清炎症因子改善情况。结果经治疗,对照组有效率为82.67%,显著低于治疗组(97.33%,P<0.05)。经治疗,在咳嗽、发热、咽部肿痛及咽部充血等症状消失时间上治疗组短于对照组(P<0.05)。经治疗,两组患者血清超敏C反应蛋白(hs-CRP)、淀粉样蛋白A(SAA)、白细胞介素-4(IL-4)、嗜酸性细胞阳离子蛋白(EOS)、降钙素原(PCT)水平均下降(P<0.05);且治疗组更显著(P<0.05)。结论小儿急性上呼吸道感染采用阿莫西林克拉维酸钾同黄栀花口服液共同治疗能够明显改善患儿临床症状,促使机体炎症消退,有着很好应用价值。

Objective To explore the clinical efficacy of Huangzhihua Oral Liquid combined with amoxicillin clavulanate potassium in treatment of acute upper respiratory tract infection in children. Methods Children(150 cases) with acute upper respiratory tract infection in Nanyang Central Hospital from January 2017 to January 2018 were divided into control(75 cases) and treatment(75 cases) groups bases on different treatments. Children in the control group were po administered with Amoxicillin and Clavulanate Potassium for Suspension, 1.5 bag/time for 7 — 12 years old children, 1 bag/time for 2 — 7 years old children, 0.5 bag/time for 9 months — 2 years old children, once every 12 h. Children in the treatment group were po administered with Huangzhihua Oral Liquid on the basis of the control group, 5 mL/time for 2 — 3 years old children, 10 mL/time for 4 — 6 years old children, 15 mL/time for 7 — 10 years old children, 20 mL/time for more than 11 years old children, three times daily. Children in two groups were treated for 7 d. After treatment, the clinical efficacy was evaluated, and the disappearance time of clinical symptoms, the serum levels of hs-CRP, SAA, IL-4, EOS and PCT in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 82.67%, which was significantly lower than 97.33% in the treatment group, and there were differences between two groups(P < 0.05). After treatment, the disappearance time of cough, fever, sore throat and congestion of the pharynx in the treatment group was significantly shorter than that in the control group(P < 0.05). After treatment, the serum levels of hs-CRP, SAA, IL-4, EOS and PCT in two groups were significantly decreased(P < 0.05), and these serum factor levels in the treatment group were significantly lower than those in the control group(P < 0.05). Conclusion Huangzhihua Oral Liquid combined with amoxicillin clavulanate potassium in treatment of acute upper respiratory tract infection in children can significantly improve the clinical symptoms and promote inflammation to subside, which has a certain clinical application value.